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INTRODUCTION TO PORTAL HYPERTENSION
SYMPOSIUM
John Terblanche, Department of Surgery and the Medical Research Council
Liver Research Centre, University of Cape Town and Groote Schuur Hospital,
Cape Town, South Africa.
This symposium overviews the longterm management of patients with portal
hypertension. Emphasis is placed on the longterm management of patients after a
variceal bleed (therapeutic management). However, the controversy whether
prophylactic management should be introduced prior to the first variceal bleed, in
the hope that this will reduce the incidence of bleeding and improve survival, is also
addressed.
Portal hypertension management remains a major challenge and poses therapeu-
tic dilemmas for both physicians and surgeons. This symposium includes the papers
presented at the symposium at the 12th Annual Meeting of the International
Hepato-Biliary-Pancreatic Association in Hong Kong in August 1990. In accepting
the challenge to present a meaningful symposium both at the IHBPA Meeting and
in print, it was my privilege to select a group of leading surgeons who have been
involved in portal hypertension management for many years and who are from
different geographic areas.
Although generally agreed that treatment is needed after a documented episode
to prevent further variceal bleeding, consensus on the best management policy is
lacking. It is important to emphasize that with the exception of hepatic transplan-
tation, no other form of therapy aimed at reducing the incidence of bleeding varices
treats the underlying liver disease and some (such as portosystemic shunting) may
even aggravate the underlying liver disease. Oesophageal varices occur in portal
hypertension caused by various aetiological cohditions with very different progno-
sis. The prevalence of causes varies geographically and thus it is important to know
the incidence of various causes in the geographic area from which results are being
reported. Probably the most common cause of portal hypertension worldwide is
schistosomiasis. As it is uncommon is most Western series and in the areas covered
by the panelists, it is not discussed in detail. However, prognosis is usually good
with proper treatment. On the other hand, alcholic cirrhosis, which is common in
Western patients, has a poor prognosis irrespective of treatment, if the patient
continues to abuse alcohol.
The important problem of acute variceal bleed management is not discussed as
the management policy is less controversial and well defined in most institutions. A
number of rare causes of portal hypertension, and the important problem of portal
hypertensive gastropathy and bleeding from the gastric mucosa are also not
addressed in this symposium.
The treatment options for patients with portal hypertension and oesophageal
varices who have had a previous bleed include conservative medical management
of the underlying liver disease awaiting a further bleed before initiating treatment;
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today); the construction of a portosystemic shunt; transection and devasculariza-
tion operations; and specific pharmacological therapy, usually aimed at lowering
portal pressure. The latter is not presented in detail in the symposium, although the
views of the panelists are presented in the Discussion. Finally, the definitive
treatment, which cures both the portal hypertension and the underlying liver
disease, is hepatic transplantation. However, as Dr Henderson emphasises, trans-
plantation is only applicable to a small subset of patients who have bleeding varices
due to portal hypertension. Nevertheless, I believe that all patients presenting with
bleeding oesophageal varices should be assessed as potential hepatic transplant
recipients because the ideal pre-transplant therapy may differ from standard
therapy if they are accepted onto a transplant programme. Here, sclerotherapy is
the preferred treatment. If other therapy is required to salvage sclerotherapy
failures the portal triad structures should be avoided, if possible, in the surgical
procedures selected.
The first two authors are surgeons with extensive expertise in both sclerothera-
phy and major portal hypertension surgery and were asked to review sclerotherapy
and the role of surgery in longterm management. Dr Henderson reviews the role of
shunting and transplantation, and Dr Idezuki the role of devascularization and
transection procedures. Both have made major personal contributions in these
areas.
I apologise to the members of the audience who took part in that their names are
not mentioned in the Discussion section because of problems with the tape
recording. I take full responsibility for any deficiencies in the Discussion but
gratefully acknowledge the help provided by the co-panelists in correcting and
updating my version of what took place.